Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.

Abstract

Purpose

Cross-sectional studies show that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies. Longitudinal data, however, are rare.

Methods

Serial echocardiograms (N = 499) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leukemia (median age at diagnosis, 4.8 years; median follow-up after completion of doxorubicin, 11.8 years). Results were expressed as z scores to indicate the number of standard deviations (SDs) above (+) or below (−) the normal predicted value. Median individual and cumulative doxorubicin doses were 30 mg/m2 per dose and 352 mg/m2, respectively.

Similar Articles

Cardiotoxicity and cardioprotection in childhood cancer

Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death

Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience

Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.

Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer

Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.

Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging

Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE

Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child

Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.

Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy

Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure

Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management

Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.